[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 12 sources · 24 days · First seen · Last updated

Telix Pharmaceuticals acquisition of ITM

Overview

Telix Pharmaceuticals has entered into an agreement to acquire ITM Isotope Technologies Munich SE in a deal valued at up to US$2.35 billion. The acquisition, which involves an upfront payment of US$1.65 billion and up to US$700 million in contingent consideration, aims to strengthen Telix’s position in the global radiopharmaceutical and radioisotope markets.

Following the proposal, Telix CEO Dr. Chris Behrenbruch characterized the merger as a “transformative step” to address the increasing global demand for therapeutic isotopes. While the announcement coincided with a 12% decline in Telix shares, the company continues to advance its clinical research, including presenting various Phase 3 studies and research into targeted alpha therapy at the European Association of Nuclear Medicine congress.

Entities

Telix Pharmaceuticals · Munich · ITM Isotope Technologies Munich SE · Indianapolis · European Association of Nuclear Medicine

Timeline

  1. [BUSINESS] 2 sources
    Telix Pharmaceuticals proposes US$2.35 billion merger with ITM

    Telix Pharmaceuticals has proposed a US$2.35 billion merger with Germany’s ITM to meet rising demand for therapeutic isotopes, alongside advancing its oncology clinical pipeline.

  2. [BUSINESS] 10 sources
    Telix Pharmaceuticals to acquire ITM in deal worth up to $2.35 billion

    Telix Pharmaceuticals to acquire Germany-based ITM Isotope Technologies Munich SE for up to US$2.35 billion to expand its global radiopharmaceutical and radioisotope production capabilities.

Sources

ad-hoc-news.de · australianmanufacturing.com.au · communitynews.com.au · cryptobriefing.com · finanzen.at · finanzen.ch · marketwire.com · pharmexec.com · raskmedia.com.au · seekingalpha.com · stockhead.com.au · theqldr.com.au